Skip to main
SBRA
SBRA logo

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 26%
Hold 39%
Sell 4%
Strong Sell 0%

Bulls say

Sabra Health Care REIT has demonstrated an improvement in its financial metrics, highlighted by a decrease in net debt to adjusted EBITDA from 5.7x to 5.3x, indicating enhanced financial stability. The transformation of its portfolio, which has fully recovered from pandemic impacts, has led to upward revisions in Core FFO estimates for 2025 and 2026, suggesting strong operational performance and growth potential. Additionally, Sabra's robust liquidity position of $953.9 million, along with a skilled nursing portfolio that shows a solid EBITDARM coverage ratio above 2x, positions the company favorably within a competitive healthcare real estate market.

Bears say

Sabra Health Care REIT is currently facing significant challenges due to high levels of debt, which could hinder its ability to meet financial obligations and adversely impact its operations. The company is exposed to various risks, including potential loss of operating licenses and reimbursement status, which could restrict revenue generation and complicate lease payment capabilities. Moreover, reliance on external capital for growth, combined with regulatory risks and competition within the REIT sector, may further limit Sabra's financial stability and recovery potential.

SBRA has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 26% recommend Buy, 39% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Buy based on their latest research and market trends.

According to 23 analysts, SBRA has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.